Loading video...

Video Failed to Load

There was a problem loading this video. This could be due to a temporary network issue or the video might be unavailable.

This video in our partnership with Dr. Glaucomflecken explains a head-to-head trial comparing rituximab versus ocrelizumab in newly diagnosed relapsing multiple sclerosis. Access the full results of the OVERLORD-MS trial for free: #neurology

NEJM

1,024,838 subscribers

34,799 views • 11 days ago •via X (Twitter)

Anya Rossi• Live Now

Private livecam show

0 Comments

No comments available

Comments from the original post will appear here

Related Videos

Our latest video in our partnership with Dr. Glaucomflecken summarizes the results of a trial investigating the effectiveness of shunt surgery for idiopathic normal-pressure hydrocephalus. Read the full results for free: #neurology

Our latest video in our partnership with Dr. Glaucomflecken summarizes the results of a trial investigating the effectiveness of shunt surgery for idiopathic normal-pressure hydrocephalus. Read the full results for free: #neurology

NEJM

56,763 views • 6 months ago

Our latest video in our partnership with Dr. Glaucomflecken summarizes a new trial investigating the mass administration of ivermectin for reducing malaria transmission. Read the full results of the BOHEMIA trial for free:

Our latest video in our partnership with Dr. Glaucomflecken summarizes a new trial investigating the mass administration of ivermectin for reducing malaria transmission. Read the full results of the BOHEMIA trial for free:

NEJM

19,398 views • 8 months ago

The latest video in our partnership with Dr. Glaucomflecken summarizes the results of the VANISH2 trial, which compared catheter ablation versus antiarrhythmic drug therapy for ventricular tachycardia. View the full article for free:

The latest video in our partnership with Dr. Glaucomflecken summarizes the results of the VANISH2 trial, which compared catheter ablation versus antiarrhythmic drug therapy for ventricular tachycardia. View the full article for free:

NEJM

50,348 views • 1 year ago

In the latest video in our partnership with Dr. Glaucomflecken, the BALANCE trial comparing 7 days of antibiotic treatment with 14 days of treatment in patients with bloodstream infection is explained. Access the article for free:

In the latest video in our partnership with Dr. Glaucomflecken, the BALANCE trial comparing 7 days of antibiotic treatment with 14 days of treatment in patients with bloodstream infection is explained. Access the article for free:

NEJM

88,431 views • 1 year ago

In the latest video in our partnership with Dr. Glaucomflecken, the INSEMA trial investigating axillary surgery in breast cancer is explained. Access the article for free:

In the latest video in our partnership with Dr. Glaucomflecken, the INSEMA trial investigating axillary surgery in breast cancer is explained. Access the article for free:

NEJM

130,645 views • 1 year ago

Our latest video in our partnership with Dr. Glaucomflecken summarizes a trial evaluating the clinical efficacy of tecovirimat against human clade II mpox. Read the full study for free:

Our latest video in our partnership with Dr. Glaucomflecken summarizes a trial evaluating the clinical efficacy of tecovirimat against human clade II mpox. Read the full study for free:

NEJM

40,735 views • 4 months ago

Could clesrovimab, a human RSV monoclonal antibody, reduce the incidence of RSV infection in preterm and full-term infants? Find out in the latest video in our partnership with Dr. Glaucomflecken. Read the full results of the CLEVER trial for free:

Could clesrovimab, a human RSV monoclonal antibody, reduce the incidence of RSV infection in preterm and full-term infants? Find out in the latest video in our partnership with Dr. Glaucomflecken. Read the full results of the CLEVER trial for free:

NEJM

46,802 views • 9 months ago

Our latest video in our partnership with Dr. Glaucomflecken summarizes a trial assessing the efficacy and safety of intravenous tenecteplase for acute central retinal artery occlusion. Read the full study for free:

Our latest video in our partnership with Dr. Glaucomflecken summarizes a trial assessing the efficacy and safety of intravenous tenecteplase for acute central retinal artery occlusion. Read the full study for free:

NEJM

34,585 views • 3 months ago

Our latest video in our partnership with Dr. Glaucomflecken summarizes the results of a trial that evaluated whether management of shock without early arterial catheterization is noninferior to the practice of early catheter insertion with regard to death from any cause at day 28. Read the full results for free:

Our latest video in our partnership with Dr. Glaucomflecken summarizes the results of a trial that evaluated whether management of shock without early arterial catheterization is noninferior to the practice of early catheter insertion with regard to death from any cause at day 28. Read the full results for free:

NEJM

47,843 views • 7 months ago

In the latest video in our partnership with Dr. Glaucomflecken, the REGENCY trial investigating the efficacy and safety of obinutuzumab when added to standard therapy in patients with active proliferative lupus nephritis is explained. Access the article for free:

In the latest video in our partnership with Dr. Glaucomflecken, the REGENCY trial investigating the efficacy and safety of obinutuzumab when added to standard therapy in patients with active proliferative lupus nephritis is explained. Access the article for free:

NEJM

144,797 views • 1 year ago

Our latest video in our partnership with Dr. Glaucomflecken summarizes the POTCAST trial, which assessed a strategy of actively increasing plasma potassium levels to the high-normal range in patients at high risk for ventricular arrhythmias. Read the full study for free:

Our latest video in our partnership with Dr. Glaucomflecken summarizes the POTCAST trial, which assessed a strategy of actively increasing plasma potassium levels to the high-normal range in patients at high risk for ventricular arrhythmias. Read the full study for free:

NEJM

89,819 views • 6 months ago

Hey, what do you think? IV or IO? This video in our partnership with Dr. Glaucomflecken summarizes new research comparing initial attempts at intraosseous or intravenous vascular access in adults who had out-of-hospital cardiac arrest. Full trial:

Hey, what do you think? IV or IO? This video in our partnership with Dr. Glaucomflecken summarizes new research comparing initial attempts at intraosseous or intravenous vascular access in adults who had out-of-hospital cardiac arrest. Full trial:

NEJM

73,368 views • 1 year ago

Phil, maybe someday 𝘺𝘰𝘶'𝘭𝘭 be functionally independent. In a new video in our partnership with Dr. Glaucomflecken, the EXPECTS trial assessing alteplase for posterior circulation ischemic stroke at 4.5 to 24 hours is explained. Access the article for free:

Phil, maybe someday 𝘺𝘰𝘶'𝘭𝘭 be functionally independent. In a new video in our partnership with Dr. Glaucomflecken, the EXPECTS trial assessing alteplase for posterior circulation ischemic stroke at 4.5 to 24 hours is explained. Access the article for free:

NEJM

66,579 views • 1 year ago

Our partnership with Dr. Glaucomflecken continues as he summarizes the final, 10-year outcomes of the CheckMate 067 trial, which investigated nivolumab plus ipilimumab in advanced melanoma. Access the article for free:

Our partnership with Dr. Glaucomflecken continues as he summarizes the final, 10-year outcomes of the CheckMate 067 trial, which investigated nivolumab plus ipilimumab in advanced melanoma. Access the article for free:

NEJM

93,576 views • 1 year ago

Our latest video in our partnership with Dr. Glaucomflecken summarizes the CORALreef Lipids trial, which assessed the efficacy of the oral PCSK9 inhibitor enlicitide in reducing LDL cholesterol levels over a 52-week period. Read the full study for free: #cardiology

Our latest video in our partnership with Dr. Glaucomflecken summarizes the CORALreef Lipids trial, which assessed the efficacy of the oral PCSK9 inhibitor enlicitide in reducing LDL cholesterol levels over a 52-week period. Read the full study for free: #cardiology

NEJM

56,926 views • 4 months ago

Internal Medicine rounds are never “aggressively boring” with Dr. G. Watch the latest video in which Dr. Glaucomflecken summarizes the PICNIC trial. Access the article for free:

Internal Medicine rounds are never “aggressively boring” with Dr. G. Watch the latest video in which Dr. Glaucomflecken summarizes the PICNIC trial. Access the article for free:

NEJM

92,522 views • 1 year ago

Which is better? Lactated Ringer’s solution or normal saline? The latest video in our partnership with Dr. Glaucomflecken summarizes the FLUID trial. 👉

Which is better? Lactated Ringer’s solution or normal saline? The latest video in our partnership with Dr. Glaucomflecken summarizes the FLUID trial. 👉

NEJM

87,546 views • 10 months ago

Hey, you should just use a triple pill, Brain Bro. Our latest video in our partnership with Dr. Glaucomflecken summarizes the TRIDENT trial that evaluated the efficacy and safety of a triple-antihypertensive pill after intracerebral hemorrhage. Read the full study for free:

Hey, you should just use a triple pill, Brain Bro. Our latest video in our partnership with Dr. Glaucomflecken summarizes the TRIDENT trial that evaluated the efficacy and safety of a triple-antihypertensive pill after intracerebral hemorrhage. Read the full study for free:

NEJM

37,701 views • 1 month ago

New in our partnership with Dr. Glaucomflecken: the KEYNOTE-905 trial evaluated enfortumab vedotin plus pembrolizumab as perioperative therapy in patients with muscle-invasive bladder cancer who were ineligible to receive cisplatin. Read the full study for free:

New in our partnership with Dr. Glaucomflecken: the KEYNOTE-905 trial evaluated enfortumab vedotin plus pembrolizumab as perioperative therapy in patients with muscle-invasive bladder cancer who were ineligible to receive cisplatin. Read the full study for free:

NEJM

104,100 views • 3 months ago

Phil, this is the kind of question with no clear answers and dozens of opinions that internists dream of! Our latest video in our partnership with Dr. Glaucomflecken summarizes the Ez-PAVE trial that evaluated the appropriate LDL cholesterol target for secondary prevention in patients with atherosclerotic cardiovascular disease. Read the full study for free: #Cardiology

Phil, this is the kind of question with no clear answers and dozens of opinions that internists dream of! Our latest video in our partnership with Dr. Glaucomflecken summarizes the Ez-PAVE trial that evaluated the appropriate LDL cholesterol target for secondary prevention in patients with atherosclerotic cardiovascular disease. Read the full study for free: #Cardiology

NEJM

49,706 views • 2 months ago